3-(3,8-二氨基-5-苯基菲啶-5-鎓-6-基)丙基-二乙基-甲基铵 | 36015-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 3-(3,8-二氨基-5-苯基菲啶-5-鎓-6-基)丙基-二乙基-甲基铵
• 英文名称: propidium
• 英文别名: 3-(8-azaniumyl-3-imino-6-phenylphenanthridin-5-yl)propyl-diethyl-methylazanium
• CAS: 36015-30-2
• 化学式: C₂₇H₃₄N₄
• 分子量: 414.594
• InChiKey: ZDWVWKDAWBGPDN-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.9
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  hydropropidine 在 二乙烯三胺五醋酸 、 四氯苯醌 作用下， 以 aq. phosphate buffer 为溶剂， 生成 3-(3,8-二氨基-5-苯基菲啶-5-鎓-6-基)丙基-二乙基-甲基铵
  参考文献：
  名称：

  Hydropropidine: A novel, cell-impermeant fluorogenic probe for detecting extracellular superoxide

  摘要：

  Here we report the synthesis and characterization of a membrane-impermeant fluorogenic probe, hydropropidine (HPr+), the reduction product of propidium iodide, for detecting extracellular superoxide (O-2(center dot-)). HPr+ is a positively charged water-soluble analog of hydroethidine (HE), a fluorogenic probe commonly used for monitoring intracellular O-2(center dot-). We hypothesized that the presence of a highly localized positive charge on the nitrogen atom would impede cellular uptake of HPr+ and allow for exclusive detection of extracellular O-2(center dot-). Our results indicate that O-2(center dot-) reacts with HPr+ (k=1.2 x 10(4) M-1 s(-1)) to form exclusively 2-hydroxypropidium (2-OH-Pr2+) in cell-free and cell-based systems. This reaction is analogous to the reaction between HE and O-2(center dot-) (Zhao et al., Free Radic. Biol. Med. 34:1359-1368; 2003). During the course of this investigation, we also reassessed the rate constants for the reactions of O-2(center dot-) with HE and its mitochondria targeted analog (Mito-HE or MitoSOX Red) and addressed the discrepancies between the present values and those reported previously by us. Our results indicate that the rate constant between O-2(center dot-) and HPr+ is slightly higher than that of HE and O-2(center dot-) and is closer to that of Mito-HE and O-2(center dot-). Similar to HE, HPr+ undergoes oxidation in the presence of various oxidants (peroxynitrite-derived radicals, Fenton's reagent, and ferricytochrome c) forming the corresponding propidium dication (Pr2+) and the dimeric products (e.g., Pr2+-Pr2+). In contrast to HE, there was very little intracellular uptake of HPr+. We conclude that HPr+ is a useful probe for detecting O-2(center dot-) and other one-electron oxidizing species in an extracellular milieu. (C) 2012 Published by Elsevier Inc.

  DOI：

  10.1016/j.freeradbiomed.2012.09.018

文献信息

• Ataxia Telengiectasia And RAD3-Related (ATR) Inhibitors And Methods Of Their Use
  申请人：Atrin Pharmaceuticals LLC

  公开号：US20170291911A1

  公开（公告）日：2017-10-12

  The disclosure is directed to compounds and compositions that inhibit Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase and methods of their use.

  该披露涉及抑制共济失调毛细血管扩张性和Rad3相关蛋白激酶（ATR）的化合物和组合物，以及它们的使用方法。
• Sulfur containing compounds
  申请人：——

  公开号：US20030220524A1

  公开（公告）日：2003-11-27

  This invention is directed to novel and known stufur containing compounds and pharmaceutically acceptable salts thereof that have utility as antifungals and as antiproliferative agents against mammalian cells, in particular cancer cells and most particularly leukemia-derived cells. The invention provides a method for synthesizing certain of the sulfur containing compounds that is more efficient than previously known methods.

  这项发明涉及新颖且已知的含有硫的化合物以及具有抗真菌活性和作为哺乳动物细胞，特别是癌细胞，尤其是白血病来源细胞的抗增殖剂的药用可接受盐。发明提供了一种合成某些含硫化合物的方法，该方法比先前已知的方法更有效。
• SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY
  申请人：Northwestern University

  公开号：US20170001976A1

  公开（公告）日：2017-01-05

  Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated glucocerebrosidase conjugated to the small molecules, which compositions may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease.

  公开了具有取代喹唑啉核心结构的新小分子，以及它们用于调节葡萄糖苷脂酶活性的用途。还公开了包含这些小分子或与小分子结合的激活葡萄糖苷脂酶的药物组合物，这些组合物可以用于治疗与葡萄糖苷脂酶活性相关的疾病或失调，包括神经系统疾病和失调，如戈谢病和帕金森病。
• [EN] PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS<br/>[FR] COMPOSÉS PHARMACEUTIQUES POUR LE TRAITEMENT DE TROUBLES MÉDIÉS PAR LE COMPLÉMENT
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2020198062A1

  公开（公告）日：2020-10-01

  This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl -mediated disorders.

  这份披露提供了用于治疗医学疾病的药物化合物，例如包括补体介导的疾病在内的补体Cl-介导的疾病。
• COMPOUND FOR PROMOTING APOPTOSIS OF CANCER CELLS AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND USES THEREOF
  申请人：NATIONAL CHIAO TUNG UNIVERSITY

  公开号：US20160068495A1

  公开（公告）日：2016-03-10

  The present invention provides a compound of Formula (I) and a salt thereof, wherein, m is an integer of 2 to 7, and R is independently at least one selected from the group consisting of hydrogen and C 1 -C 20 alkyl. The compound promotes apoptosis in cancer cell and inhibits its growth. The present invention also provides a pharmaceutical composition which comprises the compound of Formula (I), a salt thereof and a pharmaceutically acceptable carrier. The present invention further provides a method for production of the pharmaceutical composition used for treating cancer.

  本发明提供了一种式（I）的化合物及其盐， 其中，m为2至7的整数，R独立地至少选择自氢和C 1 -C 20 烷基的群组中的一种。该化合物促进癌细胞凋亡并抑制其生长。本发明还提供了一种包括式（I）的化合物、其盐和药学上可接受的载体的药物组合物。本发明进一步提供了一种用于治疗癌症的药物组合物的生产方法。